Global Roundup: Memo Therapeutics Takes Aim at BKV Infections
Memo Therapeutics, a Switzerland-based antibody discovery and development company, initiated a Phase I study that will evaluate intravenous doses of the experimental MTX-005 that targets BK polyomavirus (BKV) infection in renal transplant patients. The study will...
FDA Pushes Designation Status for Cancer, Hemophilia Treatments
The U.S. Food and Drug Administration (FDA) is on a mission to recuperate from the review lag seen through the early phases of COVID-19 pandemic and has provided special designations for two treatments that could improve the lives of millions with recurrent...
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Cybin Inc, a biopharmaceutical company focused on progressing effective therapeutics for patients, is submitting an Investigational New Drug application to the U.S. Food and Drug Administration for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a...
Exploring the Causal Connection Between COVID-19 and Diabetes
Research involving a causal link between COVID-19 and diabetes has surfaced in a study published in The Lancet Diabetes & Endocrinology in March. Researchers gathered results showing people who suffered from COVID-19 were 40% more likely than controls to develop...
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® Cosmetic Technology in Dermal Resurfacing Procedures
Apyx Medical Corporation, a manufacturer of medical devices and supplies and the innovator of Helium Plasma Technology, marketed and sold as Renuvion® and J-Plasma® in surgical markets, today announced it has received 510(k) clearance from the U.S. Food and Drug...
FDA Hits Verrica With Third CRL For Lead Drug Candidate VP-102
Verrica Pharmaceuticals has obtained its third Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its New Drug Application for its molluscum contagiosum treatment candidate VP-102. The first CRL was distributed in July 2020 as the FDA...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com